Skip to content

Study on the integrated disease-syndrome characteristics and metabolomics of type 2 inflammatory chronic obstructive pulmonary disease in stable phase

Study on the integrated disease-syndrome characteristics and metabolomics of type 2 inflammatory chronic obstructive pulmonary disease in stable phase

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123521
Enrollment
Unknown
Registered
2026-04-27
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

Type 2 Inflammatory Group:None
Non-type 2 Inflammatory Group:None

Sponsors

The First Affiliated Hospital of Henan university of Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the western diagnostic criteria for chronic obstructive pulmonary disease (COPD) at stable stage. 2. Age between 18 and 80 years old. 3. Voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Comorbidities associated with elevated blood eosinophils, including allergic diseases such as allergic asthma and allergic rhinitis, infectious diseases such as parasitic infections, hematological diseases such as Hodgkin’s disease, eosinophilic leukemia, and hypereosinophilic syndrome, immune system diseases such as eosinophilic granulomatosis with polyangiitis, as well as other conditions judged by the investigator that may affect syndrome differentiation. 2. Complicated with severe respiratory diseases including interstitial lung disease, malignant lung tumor, pulmonary infectious disease, pneumothorax, pleural effusion, etc., or complicated with severe cardiovascular and cerebrovascular diseases, severe hepatic and renal diseases, severe hematological malignancies, etc., which affect syndrome differentiation. 3. Patients complicated with various mental disorders (such as confusion, disturbance of consciousness, dementia, etc.) that prevent normal communication, or those unable to cooperate with the investigation due to other reasons.

Design outcomes

Primary

MeasureTime frame
Forced Vital Capacity;

Secondary

MeasureTime frame
Forced Expiratory Volume in 1 second;Forced Expiratory Volume in one second / Forced Vital Capacity;Peak Expiratory Flow;Maximal Mid-Expiratory Flow;Diffusing Capacity of the Lung for Carbon Monoxide;Fractional Exhaled Nitric Oxide;White Blood Cell Count;Red Blood Cell Count;Hemoglobin;Platelet Count;Neutrophil Count;Lymphocyte Count;Eosinophil Count;

Countries

China

Contacts

Public ContactMinghang Wang

The First Affiliated Hospital of Henan university of Chinese medicine

wmh107hn@163.com+86 135 2300 3219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026